{
    "Trade/Device Name(s)": [
        "FreeStyle Libre 3 Continuous Glucose Monitoring System"
    ],
    "Submitter Information": "Abbott Diabetes Care, Inc.",
    "510(k) Number": "K212132",
    "Predicate Device Reference 510(k) Number(s)": [
        "K201761"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QLG"
    ],
    "Summary Letter Date": "April 8, 2022",
    "Summary Letter Received Date": "April 11, 2022",
    "Submission Date": "May 16, 2022",
    "Regulation Number(s)": [
        "21 CFR 862.1355"
    ],
    "Regulation Name(s)": [
        "Integrated Continuous Glucose Monitoring System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Interstitial fluid"
    ],
    "Specimen Container(s)": [
        "Sensor (applied to arm)"
    ],
    "Instrument(s)/Platform(s)": [
        "FreeStyle Libre 3 Sensor",
        "FreeStyle Libre 3 App (iOS)"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometric measurement",
        "Glucose oxidase chemical reaction",
        "Bluetooth Low Energy (BLE)",
        "Near Field Communication (NFC)"
    ],
    "Methodologies": [
        "Continuous glucose monitoring"
    ],
    "Submission Type(s)": [
        "System",
        "Sensor",
        "Mobile Application"
    ],
    "Document Summary": "FDA 510(k) summary for FreeStyle Libre 3 Continuous Glucose Monitoring System for real-time monitoring of glucose levels in interstitial fluid using factory-calibrated sensor and mobile app.",
    "Indications for Use Summary": "Real-time continuous glucose monitoring system with alarms, indicated for management of diabetes in persons aged 4 and older, intended to replace blood glucose testing for diabetes treatment decisions, aids detection of hyperglycemia/hypoglycemia, and communicates with digitally connected devices.",
    "fda_folder": "Clinical Chemistry"
}